---

ANEMIA - Comprehensive Clinical Notes

---

1. INTRODUCTION

• Decreased production of red blood cells (RBCs)
• Increased destruction of RBCs
• Acute or chronic blood loss
• Combination of the above

---

2. DEFINITION

Anemia is defined as blood hemoglobin (Hb) or red cell counts below normal for a given population.

• Harrison's Principles of Internal Medicine 22E

• A reduction in the concentration of hemoglobin, hematocrit (packed cell volume), or number of red blood cells per unit volume of blood to below the reference range for age, sex, and physiologic state.

• Hematocrit (Hct) = RBC count (per liter) × MCV ÷ 10
• Hemoglobin is the primary measure used in clinical practice

---

3. WHO HEMOGLOBIN CUT-OFF VALUES

Note: Severe maternal anemia (Hb < 6 g/dL) is associated with abnormal fetal oxygenation, non-reassuring fetal heart rate, reduced amniotic fluid, fetal cerebral vasodilatation, and fetal death. (Textbook of Family Medicine 9E)

---

4. EPIDEMIOLOGY

• Anemia affects approximately 2.4 billion people worldwide - roughly 30% of the global population.
• Approximately half of the estimated 1 billion subjects with anemia worldwide have iron deficiency as the underlying cause. (Tietz Laboratory Medicine 7E)
• Prevalence is highest in South Asia and Sub-Saharan Africa.
• Most vulnerable groups: young children, adolescent girls, pregnant women, elderly.
• In India: prevalence of anemia in women of reproductive age exceeds 50% (NFHS data).
• Iron deficiency anemia (IDA) is the single most common nutritional deficiency globally.
• Anemia of chronic disease (ACD) is the second most common cause of anemia worldwide.

• Children under 5: ~40% affected
• Pregnant women: ~38% globally
• Non-pregnant women 15-49 years: ~29%
• Men: ~12-15%

---

5. CLASSIFICATION OF ANEMIA

A. MORPHOLOGICAL CLASSIFICATION (by MCV)

ANEMIA
   |
   |-------- MICROCYTIC (MCV < 80 fL) --------
   |         - Iron deficiency anemia (IDA)
   |         - Thalassemia (alpha & beta)
   |         - Anemia of chronic disease (some)
   |         - Sideroblastic anemia
   |         - Lead poisoning
   |
   |-------- NORMOCYTIC (MCV 80-100 fL) ------
   |         - Anemia of chronic disease
   |         - Aplastic anemia
   |         - Hemolytic anemia
   |         - Acute blood loss
   |         - Mixed deficiency (iron + B12/folate)
   |         - Anemia of renal failure
   |         - Anemia of hypothyroidism
   |
   |-------- MACROCYTIC (MCV > 100 fL) -------
             MEGALOBLASTIC:
             - B12 deficiency
             - Folate deficiency
             - Drug-induced (methotrexate, hydroxyurea)
             NON-MEGALOBLASTIC:
             - Liver disease / alcoholism
             - Hypothyroidism
             - Myelodysplastic syndrome (MDS)
             - Reticulocytosis

B. PATHOPHYSIOLOGICAL / ETIOLOGICAL CLASSIFICATION

ANEMIA
   |
   |---- DECREASED PRODUCTION (Hypoproliferative)
   |     - Stem cell failure (aplastic anemia)
   |     - Nutritional deficiencies (iron, B12, folate)
   |     - Bone marrow infiltration (leukemia, myeloma)
   |     - Erythropoietin deficiency (renal failure)
   |     - Anemia of chronic disease/inflammation
   |     - Endocrine disorders (hypothyroidism, hypopituitarism)
   |
   |---- INCREASED DESTRUCTION (Hemolytic)
   |     INTRINSIC (RBC defects):
   |     - Membrane: Hereditary spherocytosis, elliptocytosis
   |     - Enzyme: G6PD deficiency, PK deficiency
   |     - Hemoglobin: Sickle cell disease, thalassemia
   |     EXTRINSIC:
   |     - Immune: Autoimmune hemolytic anemia (AIHA), transfusion reaction
   |     - Microangiopathic: TTP, HUS, DIC
   |     - Infectious: Malaria, Clostridium
   |     - Mechanical: Prosthetic heart valves
   |
   |---- BLOOD LOSS
         - Acute: Trauma, GI hemorrhage, surgery
         - Chronic: Menorrhagia, peptic ulcer, colorectal cancer, hookworm

C. BY BONE MARROW RESPONSE

---

6. ETIOLOGY

Iron Deficiency Anemia

• Inadequate dietary intake
• Malabsorption (celiac disease, post-gastrectomy)
• Increased demand (pregnancy, growth spurts)
• Chronic blood loss (menorrhagia, GI bleeding - peptic ulcer, colorectal cancer, NSAIDs)

Megaloblastic Anemia

• B12 deficiency: Pernicious anemia (lack of intrinsic factor), strict veganism, gastric surgery, Crohn's disease (terminal ileum involvement), fish tapeworm (Diphyllobothrium latum), drugs (metformin, PPIs)
• Folate deficiency: Poor dietary intake, alcoholism, pregnancy (increased demand), anti-folate drugs (methotrexate, trimethoprim, phenytoin), malabsorption

Anemia of Chronic Disease (ACD)

• Chronic infections (TB, HIV, osteomyelitis)
• Autoimmune diseases (RA, SLE)
• Malignancy
• Chronic kidney disease (CKD)
• Heart failure

Hemolytic Anemia

• Hereditary spherocytosis
• G6PD deficiency (triggered by oxidative stress: infections, drugs, fava beans)
• Sickle cell disease
• Thalassemia
• Autoimmune (warm/cold AIHA)
• Malaria
• TTP/HUS

Aplastic Anemia

• Idiopathic (most common ~70%)
• Drugs: chloramphenicol, sulfonamides, gold, NSAIDs
• Chemicals: benzene, pesticides
• Viral: Hepatitis, EBV, CMV, Parvovirus B19
• Autoimmune, radiation

Other Causes

• Renal failure (EPO deficiency)
• Hypothyroidism
• Myelodysplastic syndrome
• Bone marrow infiltration (leukemia, lymphoma, metastatic cancer, myelofibrosis)

---

7. RISK FACTORS

---

8. PATHOPHYSIOLOGY (Flowchart Format)

A. General Pathophysiology

UNDERLYING CAUSE (nutritional deficiency / blood loss / chronic disease / RBC destruction)
                    |
                    ↓
        REDUCED HEMOGLOBIN / RBC MASS
                    |
                    ↓
        DECREASED OXYGEN-CARRYING CAPACITY
                    |
                    ↓
            TISSUE HYPOXIA
                    |
          __________|__________
         |                     |
    COMPENSATORY           CLINICAL
    MECHANISMS             SYMPTOMS
         |
    _____|_____________________________
    |           |                     |
INCREASED    INCREASED 2,3-DPG    PLASMA VOLUME
CARDIAC      (minutes-days):      EXPANSION
OUTPUT       shifts O2 Hb         (weeks):
(minutes):   dissociation         maintains BP
tachycardia  curve RIGHT          and CO
             (more O2
             released
             to tissues)

B. Iron Deficiency Anemia - Step-by-step

NEGATIVE IRON BALANCE
(↓intake / ↑loss / ↑demand)
        |
        ↓
DEPLETION OF IRON STORES
(↓serum ferritin, ↓bone marrow iron)
        |
        ↓
IRON-DEFICIENT ERYTHROPOIESIS
(↑TIBC, ↑sTfR, ↓serum iron, ↓transferrin saturation)
        |
        ↓
IRON DEFICIENCY ANEMIA
(↓Hb, ↓MCV, ↓MCH, ↓MCHC → microcytic hypochromic RBCs)
        |
        ↓
TISSUE IRON DEFICIENCY
(angular cheilitis, glossitis, koilonychia, pica, restless legs)

C. Anemia of Chronic Disease - Pathophysiology

CHRONIC INFLAMMATION / INFECTION / MALIGNANCY
            |
            ↓
    CYTOKINE RELEASE (IL-6, IL-1, TNF-α)
            |
         ___|___________________________
        |                              |
        ↓                              ↓
↑ HEPCIDIN (liver)           ↓ EPO PRODUCTION
        |                    (blunted response to
        ↓                    anemia in kidney)
FERROPORTIN DEGRADATION              |
(↓iron export from                   ↓
macrophages/enterocytes)    REDUCED ERYTHROPOIESIS
        |                            |
        ↓                            ↓
IRON SEQUESTRATION          ↓ RBC PRODUCTION
(iron trapped in RES,
↓serum iron, ↓TIBC,
↑serum ferritin)
        |_____________________________|
                    |
                    ↓
        NORMOCHROMIC NORMOCYTIC ANEMIA
        (occasionally microcytic)

---

9. CLINICAL MANIFESTATIONS

General / Universal Symptoms (Due to Tissue Hypoxia)

• Fatigue and easy fatigability (most common)
• Weakness
• Dyspnea on exertion (later, dyspnea at rest)
• Palpitations
• Dizziness / lightheadedness
• Headache
• Difficulty concentrating / poor memory
• Syncope (severe cases)

• Pallor: conjunctiva, mucous membranes, nail beds, palmar creases
• Tachycardia (resting)
• Cardiac flow murmur (high-output state)
• Bounding pulse
• Wide pulse pressure
• Edema (in severe/chronic cases - high-output heart failure)

Symptoms Specific to Cause

---

10. DIAGNOSIS

Step 1: History

• Previous episodes of anemia, prior transfusions, iron therapy
• Menstrual history (duration, clots, number of pads)
• Family history (thalassemia, sickle cell, G6PD)
• Diet history (vegetarian/vegan)
• Drug history (NSAIDs, chemotherapy, metformin)
• GI symptoms (diarrhea, blood in stool - celiac, IBD, colorectal cancer)
• Symptoms of chronic disease

Step 2: Physical Examination

• General: Pallor of conjunctiva, mucous membranes, nail beds
• Cardiovascular: Tachycardia, flow murmur, bounding pulse
• Abdominal: Splenomegaly (hemolytic anemia, thalassemia), hepatomegaly
• Neurological: Peripheral neuropathy, posterior column signs (B12)
• Specific signs: Koilonychia, angular cheilitis, jaundice, bone tenderness

Step 3: Diagnostic Algorithm

Complete Blood Count (CBC)
          |
          ↓
Check Hemoglobin → LOW? (meets WHO criteria for anemia)
          |
          ↓
       MCV (red cell size)
     _____|___________________________________________
    |                 |                             |
MICROCYTIC        NORMOCYTIC                   MACROCYTIC
(MCV < 80)       (MCV 80-100)                 (MCV > 100)
    |                 |                             |
Check             Check                      Blood smear:
Ferritin,         Reticulocyte               Hypersegmented
Serum iron,       count                      neutrophils?
TIBC, RDW             |                           |
    |          _______|_______              YES         NO
    |         |               |             |            |
Low       HIGH reticulocyte  LOW        Check B12    Round
ferritin  (>2%)              (<2%)      & Folate  macrocytes →
    ↓           |               |                 Liver disease,
  IDA    Check blood       Check Renal            Alcohol,
         smear:            function,             Hypothyroidism,
         Sickle,           EPO level,            MDS (→ bone
         spherocytes,      SPEP, TSH,            marrow biopsy)
         fragmented    Bone marrow exam
         cells         if no cause found

---

11. LABORATORY INVESTIGATIONS

Tier 1 - Baseline (All patients)

Tier 2 - Directed by MCV/Smear

Tier 3 - Advanced / Specialist

Key Lab Patterns Summary

---

12. MANAGEMENT

Goals of Therapy

1. Correct hemoglobin and hematocrit to age/sex-appropriate levels
2. Replenish depleted stores (e.g., iron stores in IDA, B12 in megaloblastic anemia)
3. Relieve symptoms of anemia (fatigue, dyspnea, palpitations)
4. Treat the underlying cause (most important - without this, recurrence is inevitable)
5. Prevent complications (cardiac failure, cognitive impairment, fetal compromise, impaired immunity)
6. Restore quality of life and functional capacity

---

Non-Pharmacological Treatment

---

Pharmacological Treatment

A. Iron Deficiency Anemia

• Drug of choice: Ferrous sulfate 325 mg (contains ~65 mg elemental iron) three times daily
• Other oral salts: Ferrous gluconate (325 mg = ~38 mg elemental), Ferrous fumarate (200 mg = ~66 mg elemental)
• Dose: 150-200 mg elemental iron per day in 2-3 divided doses
• Duration: Until Hb normalizes, then continue for 3-6 months to replenish stores
• Take: 1 hour before or 2 hours after meals for best absorption (or with small amount of food if GI side effects)
• Enhancers: Take with Vitamin C (ascorbic acid 200 mg)
• Side effects: Nausea, constipation, dark stools, epigastric discomfort, diarrhea

New evidence (2024): Alternate-day iron dosing has been shown to be as effective as daily dosing while reducing GI side effects and improving hepcidin kinetics. (Systemic evidence supports alternate-day dosing)

• Indications: Intolerance to oral iron, malabsorption (celiac disease, post-bariatric surgery), inflammatory bowel disease, ongoing blood loss exceeding oral replacement, pre-operative optimization, non-compliance
• Agents: Ferric carboxymaltose (FCM), Iron sucrose, Low molecular weight iron dextran, Ferric derisomaltose
• Ferric Carboxymaltose: 15 mg/kg up to 1000 mg in a single dose; particularly useful in moderate-severe IDA
• A 2024 meta-analysis showed IV ferric carboxymaltose is highly effective for moderate/severe anemia with good safety profile (PMID: 38405188)
• Monitoring: Serum ferritin and transferrin saturation 4-8 weeks post-infusion

B. Megaloblastic Anemia

• IM Cyanocobalamin or Hydroxocobalamin: 1000 mcg IM daily for 7 days, then weekly for 4 weeks, then monthly for life (if pernicious anemia or malabsorption)
• Oral high-dose B12 (1000-2000 mcg/day): effective even in pernicious anemia due to passive absorption; can substitute for IM in non-severe cases
• Response: Reticulocyte count rises in 3-5 days; Hb normalizes in 6-8 weeks; neurological recovery is slower (weeks to months) and may be incomplete

• Folic acid 1-5 mg orally daily for 4 months
• Prevention in pregnancy: 400 mcg daily pre-conception and through first trimester (5 mg in high-risk women - prior NTD, epilepsy, diabetes)
• IMPORTANT: Do NOT give folate alone if B12 deficiency has not been ruled out - may correct hematological findings while allowing neurological damage to progress

C. Anemia of Chronic Disease (ACD)

• Primary treatment: Treat the underlying condition
• Erythropoiesis-Stimulating Agents (ESAs):
  • Recombinant EPO (Epoetin alfa), Darbepoetin alfa
  • Indications: CKD-related anemia (Hb < 10 g/dL), chemotherapy-induced anemia, MDS
  • Target Hb: 10-12 g/dL (avoid normalization - associated with increased cardiovascular risk)
  • Must ensure adequate iron stores before/during ESA therapy
• IV iron supplementation: Indicated when transferrin saturation < 30% or ferritin < 500 ng/mL in renal patients (Goldman-Cecil Medicine)

D. Hemolytic Anemia

• AIHA (Warm type): Corticosteroids (prednisolone 1 mg/kg/day) first-line; Rituximab second-line; Splenectomy for refractory cases
• AIHA (Cold type): Avoid cold exposure; Rituximab; Sutimlimab (complement inhibitor - approved 2022)
• G6PD deficiency: Avoid triggering agents; supportive care; blood transfusion if severe
• Hereditary spherocytosis: Folic acid supplementation; splenectomy for severe cases

E. Aplastic Anemia

• Mild-Moderate: Horse anti-thymocyte globulin (hATG) + cyclosporine + eltrombopag
• Severe/Very severe: Allogeneic hematopoietic stem cell transplantation (HSCT) - best for age < 40 with matched donor
• Supportive: RBC transfusions, platelet transfusions, G-CSF, antimicrobials

F. Sickle Cell Disease

• Hydroxyurea: First-line disease-modifying therapy; increases HbF, reduces crises
• Voxelotor (2019): inhibits HbS polymerization
• Crizanlizumab (2019): anti-P-selectin monoclonal antibody, reduces vaso-occlusive crises
• L-glutamine: reduces acute complications
• HSCT: Potentially curative
• Gene therapy (Betibeglogene - approved 2022): emerging curative option

G. Blood Transfusion

• Indications: Hb < 7 g/dL (or < 8 g/dL in cardiovascular disease, symptomatic), hemodynamic instability, acute hemorrhage, signs of cardiac compromise (angina), bone marrow failure requiring support
• Product: Packed Red Blood Cells (pRBCs)
• Risks: Transfusion reactions, alloimmunization, iron overload (with repeated transfusions), infection transmission, TRALI, TACO

---

13. MONITORING AND FOLLOW-UP

---

14. SPECIAL POPULATIONS (Additional Topics from Latest Evidence)

Anemia in Pregnancy

• Physiological hemodilution is normal: Hb 11 g/dL is the WHO threshold
• Recommended iron: 30 mg elemental iron daily prophylaxis; 60-120 mg daily for treatment of IDA in 2-3 divided doses (Textbook of Family Medicine)
• IV iron preferred after first trimester if oral iron fails
• A 2024 Cochrane review confirmed oral iron, IV iron, and erythropoietin are all options for postpartum IDA - choice based on severity and patient tolerance (PMID: 39670550)

Anemia in CKD

• EPO deficiency + iron deficiency + systemic inflammation are key contributors (Harrison's 22E)
• IV iron more effective than oral in dialysis patients (hepcidin impairs absorption)
• ESA target: Hb 10-11.5 g/dL - avoid targeting normal levels (increased cardiovascular events)
• Iron supplementation: when transferrin saturation < 30% or ferritin < 500 ng/mL

Anemia of Aging

• Prevalence increases sharply after age 65; ~10% of elderly have anemia
• Often multifactorial: nutritional + chronic disease + reduced EPO responsiveness
• Independently associated with increased mortality, falls, cognitive decline, hospitalization

Point-of-Care Diagnosis (2024 Evidence)

• A 2024 systematic review and meta-analysis found point-of-care hemoglobin devices have good diagnostic accuracy for detecting anemia in children in community settings, making them valuable in low-resource environments (PMID: 39556152)

Gut Microbiome and Anemia (Emerging 2024)

• A 2024 meta-analysis found that probiotic and synbiotic supplementation can modestly improve hemoglobin and ferritin levels in individuals with anemia, suggesting a role for the gut microbiome in iron absorption (PMID: 39716076)

---

Quick Reference Summary

ANEMIA = Hb below WHO threshold for age/sex/physiological state

KEY STEPS:
1. Confirm with CBC → 2. Classify by MCV → 3. Reticulocyte count →
4. Directed tests → 5. Treat CAUSE + correct deficiency → 6. Monitor

MOST COMMON: Iron deficiency anemia (IDA) - ~50% of all anemia globally

FIRST-LINE TREATMENT:
- IDA → Oral ferrous sulfate 60 mg elemental iron TID × 3-6 months
- B12 deficiency → IM cyanocobalamin 1000 mcg or high-dose oral B12
- Folate deficiency → Folic acid 1-5 mg/day
- ACD → Treat underlying cause; ESA if CKD
- Hemolytic → Steroids (AIHA); avoid triggers (G6PD)
- Aplastic → HSCT (young) or immunosuppression

---

---

ANEMIA - Complete Clinical Notes with Complications & References

---

1. INTRODUCTION

• Decreased production of red blood cells (RBCs)
• Increased destruction of RBCs (hemolysis)
• Acute or chronic blood loss
• Combination of the above mechanisms

📖 References:

• Harrison's Principles of Internal Medicine 22E, 2025, McGraw-Hill Medical
• Frameworks for Internal Medicine (Lippincott)
• Tietz Textbook of Laboratory Medicine, 7th Edition

---

2. DEFINITION

Anemia is defined as blood hemoglobin (Hb) or red cell counts below normal for a given population, age, sex, and physiological state. (Harrison's Principles of Internal Medicine 22E, Ch. 66)

• Hematocrit (%) = RBC count (per litre) x MCV / 10
• Mean Corpuscular Volume (MCV), MCH, MCHC are derived parameters used for classification

📖 References:

• Harrison's Principles of Internal Medicine 22E, Ch. 66 (ANEMIA DEFINITION AND CLASSIFICATION, block7)
• Textbook of Family Medicine 9E (ANEMIA in pregnancy, block5)

---

3. WHO HEMOGLOBIN CUT-OFF VALUES

📖 References:

• World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva: WHO, 2011.
• Harrison's Principles of Internal Medicine 22E, Ch. 66
• Frameworks for Internal Medicine (Lippincott, block2)

---

4. EPIDEMIOLOGY

• Globally ~2.4 billion people are anemic; ~30% of the world population
• Approximately half of ~1 billion anemia cases worldwide are due to iron deficiency (Tietz Textbook of Laboratory Medicine, 7E)
• Highest prevalence: South Asia and Sub-Saharan Africa
• Children under 5: ~40% affected globally
• Pregnant women: ~38% globally (WHO)
• Non-pregnant women 15-49 years: ~29% globally
• Men: ~12-15%
• In India: anemia in women of reproductive age exceeds 50% (NFHS-5 data)
• Iron deficiency anemia (IDA) = single most common nutritional deficiency worldwide
• Anemia of chronic disease (ACD) = second most common cause of anemia globally
• Anemia is "often associated with significant morbidity and mortality" (Frameworks for Internal Medicine)

📖 References:

• Tietz Textbook of Laboratory Medicine 7E (Iron Deficiency, block15, line 2763-2767)
• Frameworks for Internal Medicine (block2, line 7077-7096)
• WHO Global Anaemia Estimates, 2021

---

5. CLASSIFICATION OF ANEMIA

A. Morphological Classification (by MCV)

ANEMIA
  |
  |--- MICROCYTIC (MCV < 80 fL) ---
  |     Iron deficiency anemia (IDA)
  |     Thalassemia (alpha & beta)
  |     Anemia of chronic disease (some)
  |     Sideroblastic anemia
  |     Lead poisoning
  |
  |--- NORMOCYTIC (MCV 80-100 fL) ---
  |     Anemia of chronic disease
  |     Aplastic anemia
  |     Hemolytic anemia
  |     Acute blood loss
  |     Mixed deficiency (iron + B12/folate)
  |     Renal failure (EPO deficiency)
  |     Hypothyroidism
  |
  |--- MACROCYTIC (MCV > 100 fL) ---
        MEGALOBLASTIC:
          B12 deficiency
          Folate deficiency
          Drug-induced (methotrexate, hydroxyurea)
        NON-MEGALOBLASTIC:
          Liver disease / Alcoholism
          Hypothyroidism
          Myelodysplastic syndrome (MDS)
          Reticulocytosis (high reticulocyte count)

B. Pathophysiological Classification

ANEMIA
  |
  |--- DECREASED PRODUCTION (Hypoproliferative)
  |     Stem cell failure (aplastic anemia)
  |     Nutritional deficiency (iron, B12, folate)
  |     Bone marrow infiltration (leukemia, myeloma)
  |     EPO deficiency (renal failure)
  |     Anemia of chronic disease/inflammation
  |     Endocrine disorders
  |
  |--- INCREASED DESTRUCTION (Hemolytic)
  |     INTRINSIC (RBC defects):
  |       Membrane: Hereditary spherocytosis
  |       Enzyme: G6PD deficiency, PK deficiency
  |       Hemoglobin: Sickle cell, thalassemia
  |     EXTRINSIC:
  |       Immune: AIHA, transfusion reaction
  |       Microangiopathic: TTP, HUS, DIC
  |       Infectious: Malaria
  |       Mechanical: Prosthetic heart valves
  |
  |--- BLOOD LOSS
        Acute: Trauma, GI hemorrhage, surgery
        Chronic: Menorrhagia, PUD, colorectal cancer

C. By Bone Marrow Response

📖 References:

• Harrison's Principles of Internal Medicine 22E, Ch. 66 (ANEMIA DEFINITION AND CLASSIFICATION, block7, line 731-753)
• Tietz Textbook of Laboratory Medicine 7E, block15

---

6. ETIOLOGY

Iron Deficiency Anemia (IDA)

• Inadequate dietary intake (poor diet, strict vegetarianism)
• Malabsorption: celiac disease, post-gastrectomy/bariatric surgery
• Increased demand: pregnancy, rapid growth (infancy, adolescence)
• Chronic blood loss: menorrhagia, GI bleeding (peptic ulcer, colorectal cancer, NSAIDs, hookworm infestation)

Megaloblastic Anemia

• B12 deficiency: Pernicious anemia (anti-intrinsic factor antibodies), strict veganism, gastric surgery (loss of parietal cells), Crohn's disease (terminal ileum), fish tapeworm (Diphyllobothrium latum), drugs (metformin long-term use, PPIs, cholestyramine)
• Folate deficiency: Poor diet, alcoholism, increased demand (pregnancy, hemolytic anemia), anti-folate drugs (methotrexate, trimethoprim, phenytoin), malabsorption (celiac disease)

Anemia of Chronic Disease (ACD)

• Chronic infections: TB, HIV, osteomyelitis, endocarditis
• Autoimmune: RA, SLE, IBD
• Malignancy (tumor-related inflammation)
• Chronic kidney disease (EPO deficiency + iron sequestration)
• Heart failure

Hemolytic Anemia

• Hereditary: Spherocytosis, G6PD deficiency, sickle cell disease, thalassemia
• Acquired: Warm/cold AIHA, TTP, HUS, DIC, malaria, prosthetic valves

Aplastic Anemia

• Idiopathic (~70%)
• Drugs: chloramphenicol, sulfonamides, gold, NSAIDs
• Chemicals: benzene, pesticides
• Viral: hepatitis viruses, EBV, CMV, Parvovirus B19
• Radiation, autoimmune

Other

• CKD (reduced EPO production)
• Hypothyroidism
• Myelodysplastic syndrome (MDS)
• Bone marrow infiltration (leukemia, lymphoma, metastatic cancer, myelofibrosis)

📖 References:

• Harrison's Principles of Internal Medicine 22E, Ch. 66, 102-107
• Goldman-Cecil Medicine International Edition, block19
• Barash Clinical Anesthesia 9E (Anemia of Chronic Disease, block8)

---

7. RISK FACTORS

📖 References:

• Harrison's Principles of Internal Medicine 22E, Ch. 66, 102
• Goldman-Cecil Medicine, block35 (TABLE 199-3)
• Tietz Textbook of Laboratory Medicine 7E, block15

---

8. PATHOPHYSIOLOGY (Flowchart Format)

A. General Pathophysiology

UNDERLYING CAUSE
(Nutritional deficiency / Blood loss /
Chronic disease / RBC destruction)
              |
              ↓
   REDUCED HEMOGLOBIN / RBC MASS
              |
              ↓
   DECREASED OXYGEN-CARRYING CAPACITY
              |
              ↓
        TISSUE HYPOXIA
              |
    __________|__________
   |                     |
COMPENSATORY         CLINICAL
MECHANISMS           SYMPTOMS
   |
   |---1. INCREASED CARDIAC OUTPUT
   |   (minutes): tachycardia, bounding pulse,
   |   flow murmur; LIMITED by cardiac reserve
   |
   |---2. INCREASED 2,3-DPG
   |   (hours to days): shifts O2-Hb curve RIGHT
   |   → more O2 delivered to tissues
   |
   |---3. PLASMA VOLUME EXPANSION
       (weeks): maintains BP and CO
       but may precipitate pulmonary edema

B. Iron Deficiency Anemia - Sequential Stages

Stage 1: IRON DEPLETION
↓ Serum ferritin | ↓ Bone marrow iron stores
No anemia yet, but behavioral disturbances in children
              ↓
Stage 2: IRON-DEFICIENT ERYTHROPOIESIS
↑ TIBC | ↑ sTfR | ↓ Serum iron | ↓ Transferrin saturation
              ↓
Stage 3: IRON DEFICIENCY ANEMIA
↓ Hb | ↓ MCV | ↓ MCH | ↓ MCHC
Microcytic hypochromic RBCs on smear
High RDW (anisocytosis)
              ↓
Stage 4: TISSUE IRON DEFICIENCY
Angular cheilitis, glossitis, koilonychia, pica,
restless legs, dysphagia (Plummer-Vinson)

C. Anemia of Chronic Disease (ACD)

CHRONIC INFLAMMATION / INFECTION / MALIGNANCY
            |
            ↓
    CYTOKINES: IL-6, IL-1, TNF-α
            |
     _______|___________________________
    |                                   |
↑ HEPCIDIN (liver)               ↓ EPO PRODUCTION
    |                            (blunted renal response)
    ↓                                   |
FERROPORTIN DEGRADATION                 ↓
→ Iron trapped in RES,           REDUCED ERYTHROPOIESIS
  ↓ serum iron, ↓ TIBC,
  ↑ serum ferritin
    |___________________________________|
                   |
                   ↓
    NORMOCHROMIC NORMOCYTIC ANEMIA
    (occasionally microcytic in prolonged cases)

📖 References:

• Harrison's Principles of Internal Medicine 22E, Ch. 66 (COMPENSATION FOR ANEMIA, block7, line 505-513)
• Barash Clinical Anesthesia 9E (Anemia of Chronic Disease, block8, line 1835-1837)
• Tietz Textbook of Laboratory Medicine 7E (block15)
• Goldman-Cecil Medicine (block19)

---

9. CLINICAL MANIFESTATIONS

Universal Symptoms (All Types - Due to Tissue Hypoxia)

• Fatigue and easy fatigability (most common, earliest)
• Weakness, malaise
• Dyspnea on exertion (later, dyspnea at rest with severe anemia)
• Palpitations
• Dizziness / lightheadedness
• Headache
• Poor concentration, impaired memory
• Syncope (severe)

• Pallor: conjunctiva, mucous membranes, nail beds, palmar creases
• Tachycardia (resting)
• Cardiac flow murmur (systolic, ejection type - high output state)
• Bounding pulse and wide pulse pressure
• Edema (severe/chronic - high-output cardiac failure)

"Patients who gradually develop anemia over months can tolerate amazingly low hemoglobin levels due to compensatory mechanisms." (Harrison's 22E)

"In general, the signs and symptoms of anemia are very unreliable in predicting the patient's hematocrit." (Harrison's 22E)

Type-Specific Clinical Features

📖 References:

• Harrison's Principles of Internal Medicine 22E (SIGNS AND SYMPTOMS OF ANEMIA, block7, line 500-502)
• Goldman-Cecil Medicine, block35 (TABLE 199-3)

---

10. DIAGNOSIS

Step 1: History

• Previous episodes of anemia, transfusions, iron therapy
• Menstrual history (duration, clots, number of pads/tampons)
• Family history: thalassemia, sickle cell, G6PD deficiency
• Dietary history: vegetarian/vegan, alcohol intake
• Drug history: NSAIDs, PPIs, metformin, chemotherapy
• GI symptoms: diarrhea, blood in stool, change in bowel habit
• Symptoms of chronic disease (CKD, RA, malignancy)
• Blood donation frequency

Step 2: Physical Examination

• General: Pallor of conjunctiva, mucous membranes, nail beds
• Cardiovascular: Tachycardia, flow murmur, bounding pulse
• Abdominal: Splenomegaly (hemolytic/thalassemia), hepatomegaly, rectal exam for blood
• Neurological: Peripheral neuropathy, posterior column signs (B12 deficiency)
• Specific: Koilonychia, angular cheilitis, jaundice, bone tenderness, lymphadenopathy

Step 3: Diagnostic Algorithm

Complete Blood Count (CBC)
         |
         ↓
Hemoglobin LOW? (below WHO threshold)
         |
         ↓
Reticulocyte Count
    _____|_______________________
   |                             |
HIGH (>2%)                  LOW (<2%)
Hyperproliferative           Hypoproliferative
   |                             |
Blood loss /                Check MCV
Hemolysis                        |
   |                  ___________|___________
Check LDH,           |           |           |
haptoglobin,    MICROCYTIC  NORMOCYTIC  MACROCYTIC
Coombs,        (MCV <80)   (MCV 80-100) (MCV >100)
blood smear         |           |           |
                Ferritin,  Renal fn,  Blood smear:
                Serum Fe,  EPO level, hypersegmented
                TIBC, RDW  TSH, SPEP  neutrophils?
                    |           |           |
                Low         Anemia of  YES → B12/folate
                ferritin    CKD/ACD/   NO → Round macrocytes
                = IDA       Aplastic   → Liver disease,
                                         alcohol, MDS
                High RDW
                = IDA;
                Normal RDW
                = Thalassemia
                → Hb electrophoresis

📖 References:

• Harrison's Principles of Internal Medicine 22E (EVALUATION OF ANEMIA, block7, line 904-916)
• Harrison's 22E (LABORATORY TESTING, block7, line 516-530)

---

11. LABORATORY INVESTIGATIONS

Tier 1 - Baseline (All Patients)

Tier 2 - Directed Tests

Tier 3 - Specialist / Advanced

Key Lab Patterns Summary

📖 References:

• Harrison's Principles of Internal Medicine 22E (LABORATORY TESTING + EVALUATION, block7)
• Tietz Textbook of Laboratory Medicine 7E (Iron status tables, block15)
• Henry's Clinical Diagnosis and Management by Laboratory Methods (block17)

---

12. MANAGEMENT

Goals of Therapy

1. Correct hemoglobin and hematocrit to age/sex-appropriate levels
2. Replenish depleted stores (iron stores, B12 stores)
3. Relieve symptoms of anemia (fatigue, dyspnea, palpitations)
4. Treat the underlying cause - most critical; failure to do so leads to recurrence
5. Prevent complications (cardiac failure, cognitive impairment, fetal harm)
6. Restore quality of life and functional capacity

---

Non-Pharmacological Treatment

---

Pharmacological Treatment

A. Iron Deficiency Anemia

• Total dose: 150-200 mg elemental iron/day in 2-3 divided doses
• Duration: Until Hb normalizes, then continue 3-6 months to replenish stores
• Timing: 1 hour before or 2 hours after meals (or with small food if GI intolerance)
• Enhancer: Take with Vitamin C 200 mg
• Side effects: Nausea, constipation, dark stools, epigastric pain, diarrhea
• In pregnancy: 60-120 mg elemental iron daily in 2-3 divided doses for IDA; 30 mg daily prophylaxis (Textbook of Family Medicine 9E)

2024 Evidence - Alternate-Day Dosing: A 2024 Cochrane systematic review (57 trials, 48,971 women) confirmed oral iron during pregnancy reduces maternal anemia (RR 0.30; 95% CI 0.20-0.47) and reduces low birthweight infants (RR 0.84; 95% CI 0.72-0.99). (PMID: 39145520 - Finkelstein JL et al., Cochrane Database Syst Rev, 2024)

• Indications: Oral intolerance, malabsorption (celiac, post-bariatric), IBD, ongoing blood loss exceeding oral replacement, pre-operative optimization, dialysis patients (hepcidin blocks oral absorption)
• Agents available: Ferric carboxymaltose (FCM), Iron sucrose, Low molecular weight iron dextran, Ferric derisomaltose
• Ferric carboxymaltose dose: 15 mg/kg up to 1000 mg as a single infusion
• Monitoring: Ferritin + transferrin saturation 4-8 weeks post-infusion
• IV FCM - highly effective for moderate/severe anemia, good safety profile (PMID: 38405188)

2025 Evidence - IV Iron in Heart Failure: A landmark meta-analysis of 6 RCTs (7,175 patients) published in Nature Medicine found IV iron in heart failure patients with iron deficiency reduced composite endpoint of recurrent HF hospitalizations + cardiovascular mortality at 12 months (RR = 0.72; 95% CI 0.55-0.89). Reduced HF hospitalizations (RR = 0.69) and cardiovascular mortality (HR = 0.80) independently. (PMID: 40159279 - Anker SD et al., Nature Medicine, 2025)

B. Megaloblastic Anemia

• IM Hydroxocobalamin / Cyanocobalamin: 1000 mcg IM daily for 7 days → weekly for 4 weeks → monthly for life (pernicious anemia/malabsorption)
• Oral high-dose B12: 1000-2000 mcg/day orally (passive absorption is adequate even in pernicious anemia)
• Response timeline: Reticulocyte rise in 3-5 days; Hb normalizes in 6-8 weeks; neurological recovery slower (weeks-months), may be incomplete if delayed

• Folic acid 1-5 mg orally daily for 4 months
• Pregnancy prevention: 400 mcg/day pre-conception + first trimester; 5 mg in high-risk (prior NTD, epilepsy, diabetes)
• CRITICAL WARNING: Never give folate alone without ruling out B12 deficiency - corrects blood but allows neurological damage to progress

📖 2024 Evidence: Cochrane review on Vitamin B12 supplementation in pregnancy found benefits for maternal and infant outcomes (PMID: 38189492 - Finkelstein JL et al., Cochrane Database Syst Rev, 2024)

C. Anemia of Chronic Disease (ACD)

• Primary treatment: Treat the underlying condition first
• Erythropoiesis-Stimulating Agents (ESAs):
  • Epoetin alfa (rHuEPO), Darbepoetin alfa
  • Indications: CKD-related anemia (Hb < 10 g/dL), chemotherapy-induced anemia, MDS
  • Target Hb: 10-12 g/dL (avoid normalization - increased cardiovascular risk)
  • Must ensure adequate iron stores before initiating ESAs
  • When transferrin saturation < 30% or ferritin < 500 ng/mL, add IV iron (Goldman-Cecil Medicine)

2024 Evidence - ESA in CKD: Systematic review (Barbieri M et al., Pharmacological Research, 2024) of 24 studies found rHuEPO has neuroprotective effects in CKD - enhances brain function and improves performance on neuropsychological tests, suggesting EPO as a potential neuroprotective agent in CKD-related cognitive impairment. (PMID: 38493928)

2024 Evidence - HIF-PHI (New class): Meta-analysis of 25 trials (26,478 patients) in NEJM Evidence (2024) found Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (e.g., roxadustat, daprodustat) have comparable cardiovascular safety to ESAs in CKD. These are oral alternatives to ESA injections. (PMID: 39186635 - Ha JT et al., NEJM Evidence, 2024)

D. Hemolytic Anemia

E. Aplastic Anemia

F. Sickle Cell Disease

G. Blood Transfusion

• Indications: Hb < 7 g/dL (< 8 g/dL in cardiovascular disease); hemodynamic instability; acute hemorrhage; angina; bone marrow failure support
• Product: Packed Red Blood Cells (pRBCs) - 1 unit raises Hb ~1 g/dL
• Risks: Transfusion reactions, alloimmunization, iron overload (repeated), TRALI, TACO, infection transmission

2025 Cochrane Evidence: Restrictive transfusion strategy (Hb threshold 7-8 g/dL) is equivalent in 30-day mortality to liberal strategy (9-10 g/dL) across 61 RCTs (27,639 participants). Restrictive strategy reduces RBC transfusion exposure by 42% without increasing mortality, MI, stroke, or infection. (PMID: 41114449 - Carson JL et al., Cochrane Database Syst Rev, 2025)

---

13. COMPLICATIONS OF ANEMIA

A. Cardiovascular Complications

"Anemia and the placement of an arteriovenous fistula for hemodialysis can generate a high cardiac output state and consequent high-output heart failure." (Harrison's 22E, Cardiovascular Abnormalities, block34)

"Potentially modifiable risk factors for LVH include anemia, hypertension, extracellular volume overload." (National Kidney Foundation Primer on Kidney Diseases 8E, block6)

2025 Evidence: Meta-analysis of 6 RCTs (7,175 patients) confirmed that IV iron therapy in HF with iron deficiency significantly reduces cardiovascular hospitalizations and improves cardiac outcomes (RR = 0.72). (PMID: 40159279 - Anker SD et al., Nature Medicine, 2025)

B. Neurological / Cognitive Complications

C. Maternal and Fetal/Neonatal Complications

2024 Evidence: Meta-analysis of 18 studies (1,873 neonates) confirmed maternal anemia during pregnancy is a significant risk factor for neonatal anemia - neonatal Hb is 1.38 g/dL lower in babies born to anemic mothers (95% CI: -1.96 to -0.80, p < 0.01). (PMID: 39425056 - Zhao B et al., BMC Pregnancy Childbirth, 2024)

2024 Cochrane Evidence: Daily oral iron in pregnancy reduces maternal anemia at term (RR 0.30) and reduces iron-deficiency anemia specifically (RR 0.41), with probably little to no difference in maternal death. (PMID: 39145520 - Finkelstein JL et al., Cochrane Database Syst Rev, 2024)

D. Immunological Complications

E. Growth and Development Complications

F. Specific Disease Complications

• Vaso-occlusive crises (acute pain)
• Acute chest syndrome (life-threatening)
• Stroke (cerebrovascular occlusion)
• Avascular necrosis (femoral/humeral head)
• Splenic sequestration crisis
• Aplastic crisis (Parvovirus B19)
• Priapism
• Retinopathy
• Nephropathy / renal failure
• Leg ulcers

• Hemosiderosis: cardiac hemosiderosis (arrhythmias, cardiomyopathy), liver cirrhosis, endocrinopathies (DM, hypogonadism, hypothyroidism, adrenal insufficiency)
• Treatment: iron chelation therapy (deferoxamine, deferasirox, deferiprone)

• Pigment gallstones (bilirubin stones from chronic hemolysis)
• Aplastic crisis (superimposed Parvovirus B19 infection)
• Hemolytic crisis (in G6PD - triggered by oxidants)
• Chronic leg ulcers (sickle cell, hereditary spherocytosis)
• Pulmonary hypertension (chronic hemolysis - especially sickle cell)

• Severe bleeding (thrombocytopenia)
• Life-threatening infections (neutropenia)
• Transformation to MDS or AML (rare)
• Iron overload from repeated transfusions

G. Complications of Untreated/Severe Anemia

📖 References:

• Harrison's Principles of Internal Medicine 22E (SIGNS AND SYMPTOMS, COMPENSATION FOR ANEMIA, block7; CARDIOVASCULAR ABNORMALITIES, block34)
• National Kidney Foundation Primer on Kidney Diseases 8E (Treatment, block6)
• Goldman-Cecil Medicine (TABLE 199-3, block35)
• Swanson's Family Medicine Review (SUMMARY, block6 - sickle cell CHF)
• PMID: 40159279 (Anker SD et al., Nature Medicine, 2025)
• PMID: 39425056 (Zhao B et al., BMC Pregnancy Childbirth, 2024)
• PMID: 39145520 (Finkelstein JL et al., Cochrane Database Syst Rev, 2024)
• PMID: 38493928 (Barbieri M et al., Pharmacological Research, 2024)
• PMID: 41114449 (Carson JL et al., Cochrane Database Syst Rev, 2025)

---

14. MONITORING AND FOLLOW-UP

---

15. SPECIAL TOPICS FROM LATEST RESEARCH (2024-2026)

1. Point-of-Care Hemoglobin Testing

2. Gut Microbiome and Iron Absorption

3. HIF Prolyl Hydroxylase Inhibitors (New Oral Therapy for CKD Anemia)

4. IV Iron in Heart Failure

5. EPO as Neuroprotectant in CKD

6. Maternal Anemia and Neonatal Outcomes

7. Restrictive Transfusion Strategy

---

MASTER REFERENCE LIST

Textbook References (Primary Sources)

PubMed / Journal References (Latest Evidence 2024-2025)

---

Note on referencing: Each section above carries an inline 📖 reference citation to the specific textbook chapter and block. The PubMed evidence is cited by PMID throughout the text for traceability. All journal references are drawn from highest-evidence sources (Cochrane systematic reviews, meta-analyses in Nature Medicine, NEJM Evidence, and specialty journals), published 2024-2025.